SCHEMBL719970

SCHEMBL719970

CCc1oc2ccccc2c1C(O)C1CCCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 4/20 0.49
VKORC1 Q9BQB6 2/20 0.45
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 2/20 0.44
HSD17B10 Q99714 2/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
EYA3 Q99504 2/20 0.39
SLC22A12 Q96S37 1/20 0.39
PTPN1 P18031 2/20 0.39
CYP2D6 P10635 1/20 0.39
MEN1 O00255 2/20 0.38
HTT P42858 1/20 0.38
ABCB1 P08183 2/20 0.37
CYP2C9 P11712 2/20 0.37
BIRC5 O15392 1/20 0.37
ABCB11 O95342 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718504 0.84 CYP2C19 (0.43) CYP2C19VKORC1KMT2AALDH1A1HSD17B10
SCHEMBL720005 0.76 CYP2C19 (0.35) CYP2C19VKORC1KMT2AALDH1A1HSD17B10
SCHEMBL720515 0.73 NPC1 (0.51) CYP2C19VKORC1KMT2AALDH1A1MAPT
SCHEMBL14299512 0.73 CYP2C19 (0.54) CYP2C19KMT2AALDH1A1HSD17B10MAPT
SCHEMBL4806386 0.73 CYP2C19 (0.69) CYP2C19VKORC1ALDH1A1HSD17B10EYA3
SCHEMBL9444795 0.69 PTPN1 (0.71) CYP2C19KMT2AEYA3SLC22A12PTPN1
SCHEMBL11640926 0.69 CYP2C19 (0.50) CYP2C19KMT2AALDH1A1HSD17B10MAPT
Hydrochloric Acid SCHEMBL11637777 0.69 CYP2C19 (0.50) CYP2C19KMT2AALDH1A1HSD17B10MAPT
SCHEMBL11635688 0.68 CYP2C19 (0.49) CYP2C19KMT2AALDH1A1HSD17B10MAPT
SCHEMBL11637773 0.68 CYP2C19 (0.49) CYP2C19KMT2AALDH1A1HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP CYP2C19 946/4885VKORC1 513/4885KMT2A 1298/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP CYP2C19 946/4885VKORC1 513/4885KMT2A 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.